NTRK1 and ovarian carcinoma: Some specific antagonists, such as Ro 08-2750 (to NGF), K252a (to TrkA) or LM11A-31 (to P75), can all increase β-catenin expression by inhibiting the roles of NGF/NGFRs in ovarian cancer cells.